Hyperuricemia: Difference between revisions
Jump to navigation
Jump to search
imported>Bruce M. Tindall No edit summary |
imported>Robert Badgett No edit summary |
||
| Line 2: | Line 2: | ||
In [[medicine]], '''hyperuricemia''' is "excessive [[uric acid]] or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined ([[Lesch-Nyhan Syndrome]]). It is associated with [[hypertension]] and [[gout]]."<ref>{{MeSH}}</ref> | In [[medicine]], '''hyperuricemia''' is "excessive [[uric acid]] or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined ([[Lesch-Nyhan Syndrome]]). It is associated with [[hypertension]] and [[gout]]."<ref>{{MeSH}}</ref> | ||
Hyperuricemia may | Hyperuricemia may<ref name="pmid10815083">{{cite journal |author=Fang J, Alderman MH |title=Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey |journal=JAMA |volume=283 |issue=18 |pages=2404–10 |year=2000 |month=May |pmid=10815083 |doi= |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=10815083 |issn=}}</ref> or may not<ref name="pmid10391820">{{cite journal |author=Culleton BF, Larson MG, Kannel WB, Levy D |title=Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study |journal=Ann. Intern. Med. |volume=131 |issue=1 |pages=7–13 |year=1999 |month=July |pmid=10391820 |doi= |url=http://www.annals.org/cgi/pmidlookup?view=long&pmid=10391820 |issn=}}</ref> be associated with [[vascular disease]] and [[chronic kidney disease]]<ref name="pmid16377385">{{cite journal |author=Siu YP, Leung KT, Tong MK, Kwan TH |title=Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level |journal=Am. J. Kidney Dis. |volume=47 |issue=1 |pages=51–9 |year=2006 |month=January |pmid=16377385 |doi=10.1053/j.ajkd.2005.10.006 |url=http://linkinghub.elsevier.com/retrieve/pii/S0272-6386(05)01518-0 |issn=}}</ref>.<ref name="pmid18946066">{{cite journal |author=Feig DI, Kang DH, Johnson RJ |title=Uric acid and cardiovascular risk |journal=N. Engl. J. Med. |volume=359 |issue=17 |pages=1811–21 |year=2008 |month=October |pmid=18946066 |doi=10.1056/NEJMra0800885 |url=http://content.nejm.org/cgi/content/full/359/17/1811 |issn=}}</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 22:10, 21 February 2009
In medicine, hyperuricemia is "excessive uric acid or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (Lesch-Nyhan Syndrome). It is associated with hypertension and gout."[1]
Hyperuricemia may[2] or may not[3] be associated with vascular disease and chronic kidney disease[4].[5]
References
- ↑ Anonymous (2024), Hyperuricemia (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Fang J, Alderman MH (May 2000). "Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey". JAMA 283 (18): 2404–10. PMID 10815083. [e]
- ↑ Culleton BF, Larson MG, Kannel WB, Levy D (July 1999). "Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study". Ann. Intern. Med. 131 (1): 7–13. PMID 10391820. [e]
- ↑ Siu YP, Leung KT, Tong MK, Kwan TH (January 2006). "Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level". Am. J. Kidney Dis. 47 (1): 51–9. DOI:10.1053/j.ajkd.2005.10.006. PMID 16377385. Research Blogging.
- ↑ Feig DI, Kang DH, Johnson RJ (October 2008). "Uric acid and cardiovascular risk". N. Engl. J. Med. 359 (17): 1811–21. DOI:10.1056/NEJMra0800885. PMID 18946066. Research Blogging.